Ligence
Ligence builds Ligence Heart, an FDA-cleared and CE-marked AI platform that automates echocardiography analysis and reporting for hospital cardiology departments and PACS vendors across Europe and the US.
- Company typePrivate
- Founded2020
- HeadquartersVilnius, Lithuania
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Ligence does
Ligence is a Lithuanian deep tech / health tech company developing Ligence Heart, an FDA 510(k)-cleared and CE-marked web-based software platform that automates echocardiography (cardiac ultrasound) analysis and reporting for cardiologists and sonographers. The product applies deep learning neural networks to perform automated view classification across standard imaging planes (PLAX, A2CH, A3CH, A4CH), cardiac cycle phase detection, and a broad set of measurements including ejection fraction (EF), LV dimensions, transmitral E/A velocities, tissue Doppler, aortic valve hemodynamics, and global longitudinal peak systolic strain (GLPS). Results are delivered via DICOM SR and DICOM GSPS into existing hospital PACS, EHR, and cloud infrastructure, with automated report generation aligned to EACVI, BSE, and ASE clinical guidelines.
The company operates a vertical SaaS business model, selling annual subscriptions to hospital cardiology departments performing high volumes of 2D transthoracic echocardiography and offering an integration channel to PACS vendors seeking echocardiography-specific AI without in-house R&D investment. Pricing is quote-based rather than publicly disclosed, and a website value calculator frames the economic case around time savings (claimed at up to 50% reduction in reporting time, with customer testimonials citing ~15 minutes saved per patient). Regulatory and compliance positioning is a core commercial asset: FDA 510(k) clearance (initial plus a second for automated LV strain), CE Mark, ISO 13485, and GDPR compliance. The company has raised a €2.5 million EIC Accelerator grant (2022) and a €3 million seed round (November 2024, led by Simpact Ventures), with cumulative funding exceeding €5.5M when including earlier Lithuanian innovation grants, and is now scaling commercial operations across Europe while running US clinical trials ahead of broader American market entry.
Ligence firmographics
Firmographics- Name
- Ligence
- Legal name
- Ligence (UAB)
- Website
- https://ligence.io
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Ligence builds Ligence Heart, an FDA-cleared and CE-marked AI platform that automates echocardiography analysis and reporting for hospital cardiology departments and PACS vendors across Europe and the US.
- Ownership category
- akta.pro rank
Ligence industry classification
Industry- Product category
- Cardiac Ultrasound AI Software
- NAICS
- Software Publishers (5132)
- akta.pro primary industry
- SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
- akta.pro secondary industry
- Medical Imaging AI (HDAAAEAH)
Keywords
Where Ligence is headquartered
LocationHeadquarters
- HQ city
- Vilnius
- HQ country
- Lithuania
- HQ region
- Europe
Offices1 record
Markets served
Ligence business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Revenue model
- Ligence Heart SaaS Subscription: Ligence Heart is a web-based, out-of-the-box software solution sold as a subscription to hospitals and cardiology practices. The software automates echocardiography analysis and reporting, integrating directly with existing PACS infrastructure. Revenue is generated through per-echo or subscription-based pricing, with value calculators suggesting per-study economics.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise/SaaS subscription for hospital cardiology departments |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Ligence product offering
Product offeringCore offering
Ligence develops Ligence Heart™, an FDA Cleared and CE-Marked web-based software that uses deep learning neural networks to automatically analyze 2D transthoracic echocardiography (2D TTE) images. The product classifies cardiac views, detects heart cycle phases, performs automated measurements (e.g., ejection fraction, LV dimensions, strain), and generates guideline-based echocardiography reports (EACVI, BSE, ASE) for hospital cardiology departments and PACS vendors.
Product overview
Ligence offers a unified cardiac diagnostics platform centered on Ligence Heart™, an FDA Cleared and CE-Marked echocardiography analysis software. The core product automates cardiac ultrasound analysis using deep learning for view classification, image segmentation, and automated measurements. An add-on module, Ligence Heart for PACS, extends these capabilities to external PACS systems through DICOM integration. The platform generates structured diagnostic reports following clinical guidelines (EACVI, BSE, ASE) and targets cardiologists and sonographers to reduce echocardiography reporting time and improve diagnostic accuracy.
Differentiator
Problem solved
Functional benefit
Products and services
- Ligence Heart™ FDA Cleared and CE-Marked web-based echocardiography analysis and reporting software that automates cardiac ultrasound image analysis using deep learning. It classifies heart views (PLAX, A2CH, A3CH, A4CH), detects systolic and diastolic phases, performs automated measurements (EF, LV dimensions, transmitral E/A velocities, tissue Doppler, strain), and generates structured reports following EACVI, BSE, or ASE guidelines for cardiologists and sonographers.
- Ligence Heart for PACS Integration module for PACS vendors and radiology networks that embeds Ligence's automated echocardiography measurements and analysis into PACS platforms via DICOM SR/GSPS formats, including an HTML5 DICOM viewer. Designed for PACS companies seeking to add AI-powered echocardiography capability without in-house R&D investment.
Quantifiable outcome
- 15 minutes saved per patient in echocardiography reporting
- +2 more outcomes
Companies that use Ligence
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Ligence technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability4 records
Feature7 records
Ligence partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered partner.
- ClariuspartnerClarius is listed as a partner on Ligence's website. Clarius produces handheld ultrasound scanners, and the partnership likely involves integration of Ligence's AI-powered echocardiography analysis with Clarius ultrasound devices.
- CARPLpartnerCARPL is listed as a partner on Ligence's website. CARPL is a radiology AI platform that enables integration of multiple AI models; the partnership likely involves CARPL hosting or distributing Ligence's cardiac AI within its platform ecosystem.
- DeepCpartnerDeepC is listed as a partner on Ligence's website. DeepC provides a deep learning infrastructure platform, and the partnership may relate to AI model deployment, training infrastructure, or joint go-to-market in the radiology AI space.
Scale indicators4 records
Recent moves8 records
Expansion highlights6 records
Ligence competitors and assessment
Company assessmentDirect peers
- Caption Health: AI-powered echocardiography guidance and analysis software, acquired by GE HealthCare in 2024. Direct competitor in automated cardiac ultrasound measurement and reporting for cardiology workflows.
- Ultromics: UK-based AI echocardiography company offering EchoWeave and EchoGo for automated cardiac analysis including strain and HFpEF detection. Directly competes with Ligence Heart in automated echo measurement and reporting for hospital cardiology departments.
- Us2.ai: Singapore-based AI echocardiography platform automating cardiac measurements and reporting for clinical and clinical trial use. Competes head-to-head with Ligence Heart in automated echo analysis.
- TOMTEC Imaging Systems: Echocardiography analysis software (now part of Philips) automating 2D/3D cardiac measurements including strain and 3D volumes. Long-standing specialist peer in clinical echo analysis and reporting that Ligence competes with directly.
Broad incumbents
- Philips (HeartModel / EPIQ CVx AI): Global ultrasound OEM integrating AI-based cardiac quantification (e.g., HeartModel) into its EPIQ/Affiniti platforms. A broad incumbent that bundles AI echo features natively into PACS-connected systems, putting competitive pressure on standalone AI vendors like Ligence.
- GE HealthCare: Global imaging OEM and ultrasound vendor that acquired Caption Health. Competes with Ligence by bundling AI-driven echo automation into its Vscan Air and premium ultrasound consoles plus Centricity PACS.
- Siemens Healthineers (AI-Rad Companion / eSie Measure): Cardiac imaging AI features integrated into Siemens ACUSON ultrasound and syngo.via platforms, providing automated echo measurements and broader radiology AI that overlaps with Ligence's analysis-and-reporting value proposition.
Emerging players
- Circle Cardiovascular Imaging: AI-driven cardiac MR and CT analysis platform. Overlaps with Ligence's automated measurement approach and represents a cross-modality competitor that could expand into echo.
- HeartVista: AI-driven cardiac MRI acquisition and analysis platform. Comparable in clinical AI positioning and FDA-clearance trajectory, with potential future overlap in multi-modality cardiac diagnostics.
Regional players
- EchoNous: AI-enabled handheld/portable ultrasound with embedded cardiac measurement automation. Comparable in combining AI with echo to automate cardiac workflows, but sold more as a device-plus-AI bundle rather than pure software like Ligence Heart.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Ligence social profiles
Digital presenceLigence compliance and trust
Trust signalCompliance4 records
Ligence financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ligence leadership team
Management profileNumber of profiles
Profiles5 records
Ligence funding detail
Funding detailFunding overview
Funding rounds11 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ligence M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ligence
What does Ligence do?
Ligence develops Ligence Heart™, an FDA Cleared and CE-Marked web-based software that uses deep learning neural networks to automatically analyze 2D transthoracic echocardiography (2D TTE) images. The product classifies cardiac views, detects heart cycle phases, performs automated measurements (e.g., ejection fraction, LV dimensions, strain), and generates guideline-based echocardiography reports (EACVI, BSE, ASE) for hospital cardiology departments and PACS vendors.
Is Ligence a public or private company?
Ligence is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ligence founded?
Ligence was founded in 2020. It employs 1 to 10 people.
Where is Ligence based?
Ligence is headquartered in Vilnius, Lithuania, in the Europe region.
How does Ligence make money?
One revenue line is on record: ligence Heart SaaS Subscription.
Who are Ligence's main competitors?
Direct peers on record are Caption Health, Ultromics, Us2.ai and TOMTEC Imaging Systems. Broad incumbents are Philips (HeartModel / EPIQ CVx AI), GE HealthCare and Siemens Healthineers (AI-Rad Companion / eSie Measure). Emerging players are Circle Cardiovascular Imaging and HeartVista. EchoNous is listed as a regional player.
Does Ligence have an API?
No public API is recorded for Ligence.
What industry is Ligence in?
Ligence's product category is Cardiac Ultrasound AI Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 5132.